366 completed, 66 terminated, 59 unknown, 48 recruiting. 119 Phase 2, 112 Not applicable, 97 Phase 3, 81 Phase 4, 59 Phase 1.
Follow this condition Literature Review of Multiple Sclerosis, Relapsing-Remitting trials Research Report on Multiple Sclerosis, Relapsing-Remitting
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS Remibrutinib (Open Label) - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive | Phase 2 | Not yet recruiting | Moein Amin | 20 | 2027-03-01 | 2026-08-19 |
| Clinnova-MS: A Prospective Cohort Study of Patients With Multiple Sclerosis: A Trans-regional Digital Health Effort Unlocking the Potential of Artificial Intelligence and Data Science in Health Care Cohort - Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Chronic Progressive | Not yet recruiting | Luxembourg Institute of Health | 100 | 2026-12-01 | 2026-09-22 | |
| Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis Behavioural intervention for physical activity for multiple sclerosis (BIPAMS) - Multiple Sclerosis, Relapsing-Remitting, Sexual Dysfunction | Not applicable | Not yet recruiting | University of Alabama at Birmingham | 30 | 2026-12-01 | 2025-12-22 |
| A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) Ocrelizumab co-formulated with rHuPH20 - Relapsing-remitting Multiple Sclerosis | Phase 2 | Not yet recruiting | Hoffmann-La Roche | 25 | 2026-10-30 | 2026-10-14 |
| Non-interventional Study of Subcutaneous Ocrelizumab in Persons With Relapsing-Remitting Multiple Sclerosis Ocrelizumab - Relapsing-Remitting Multiple Sclerosis | Recruiting | Hoffmann-La Roche | 1800 | 2026-09-30 | 2026-09-28 | |
| Sociocognitive Intervention and Rehabilitation Program in Multiple Sclerosis Sociocognitive rehabilitation via COGWEB platform combined with an emotional processing intervention. - Multiple Sclerosis | Not applicable | Not yet recruiting | Sonia Batista | 130 | 2026-09-01 | 2026-07-29 |
| The HIt HArd and hiT Early in Multiple Sclerosis Trial Sequential treatment with rituximab and cladribine - Relapsing-remitting Multiple Sclerosis | Phase 2 | Recruiting | Uppsala University | 60 | 2026-09-01 | 2026-10-08 |
| Multicenter Prospective Study Analyzing the Occurrence of Multiple Sclerosis Relapses Without Radiological Evidence: Myth or Reality? Early Cerebro-spinal MRI, Biomarker Assessment, Clinical and Neuropsychological Evaluations - Multiple Sclerosis, RRMS | Not applicable | Not yet recruiting | University Hospital, Strasbourg, France | 136 | 2026-09-01 | 2026-04-22 |
| Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis. Remibrutinib, Ocrelizumab (US) - Multiple Sclerosis (MS) - Relapsing-remitting | Recruiting | Washington University School of Medicine | 15 | 2026-08-15 | 2026-08-11 | |
| A Study to Evaluate the Preliminary Efficacy and Safety of Terfenadine in Patients With Relapsing-Remitting Multiple Sclerosis Terfenadine, Standard First-line Disease-Modifying Therapy - Relapsing Remitting Multiple Sclerosis | Phase 2 | Recruiting | Chuan Qin | 100 | 2026-08-15 | 2026-09-18 |
| A Study of Rocbrutinib in PRL-Positive Relapsing-Remitting Multiple Sclerosis Rocbrutinib, Dimethyl Fumarate - Relapsing-remitting Multiple Sclerosis (RRMS) | Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 30 | 2026-08-01 | 2026-08-20 |
| Effects of Powered Hip Flexion Device in Persons With Multiple Sclerosis Powered Hip Flexion Orthosis (Hypershell X) - Multiple Sclerosis (MS) Relapsing Remitting | Not applicable | Not yet recruiting | University of Dayton | 10 | 2026-07-15 | 2026-07-23 |
| Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple Sclerosis Blood Flow Restriction Training, Sham Blood Flow Restriction, Low-Load Exercise Program - Multiple Sclerosis (MS) - Relapsing-remitting | Not applicable | Not yet recruiting | Hanifi Bal | 30 | 2026-07-01 | 2026-06-12 |
| PRIMUS : Real World Usage for Real World Evidence of CDSS Use in Multiple Sclerosis Clinical decision support system - Relapsing - Remitting Multiple Sclerosis | Not applicable | Not yet recruiting | Nantes University Hospital | 448 | 2026-06-30 | 2026-06-15 |
| A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis Platform therapies (Dimethyl Fumarate, Teriflunomide, Glatiramer Acetate, Beta-interferons), Anti-CD20 therapies (Ocrelizumab, Rituximab, Ofatumumab) - Relapsing-Remitting Multiple Sclerosis (RRMS), Anti-CD20 Therapy | Phase 3 | Recruiting | University Hospital, Montpellier | 250 | 2026-06-15 | 2026-06-23 |
| Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis Acute Intermittent Hypoxia (AIH), Sham Acute Intermittent Hypoxia (AIH), Myoelectric Interface Neurorehabilitation Training (MINT) - Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting | Not applicable | Not yet recruiting | Shirley Ryan AbilityLab | 35 | 2026-06-15 | 2026-06-08 |
| RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis CABA-201 - Relapsing Multiple Sclerosis (RMS), Progressive Multiple Sclerosis (PMS) | Phase 1 / Phase 2 | Withdrawn | Cabaletta Bio | 2026-06-01 | 2026-06-25 | |
| Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis Ublituximab, Other disease modifying therapies - Multiple Sclerosis (MS) - Relapsing-remitting | Not applicable | Recruiting | University of Maryland, Baltimore | 30 | 2026-05-01 | 2026-07-29 |
| The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study Implant Procedure, Disease-Modifying Therapies (DMTs), Active stimulation - Relapsing Remitting Multiple Sclerosis | Not applicable | Recruiting | SetPoint Medical Corporation | 60 | 2026-04-17 | 2026-09-02 |
| Healthy Eating and Active Living for People Living With Multiple Sclerosis (HEAL MS): A Lifestyle Program for People With Multiple Sclerosis Multi-Domain Lifestyle Intervention - Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis | Not applicable | Not yet recruiting | New York University Abu Dhabi | 30 | 2026-04-15 | 2026-05-15 |
Showing 20 of 612. Sign in to see all of them.
Multiple Sclerosis (301) · Multiple Sclerosis, Chronic Progressive (70) · Fatigue (28) · Demyelinating Diseases (16) · Motor Activity (13) · Nervous System Diseases (12) · Recurrence (12) · Autoimmune Diseases (11) · Cognitive Dysfunction (9) · Depression (7) · Autoimmune Diseases of the Nervous System (6) · Inflammation (6) · Anxiety Disorders (5) · Disease Progression (5)
Demyelinating Autoimmune Diseases, CNS (608) · Immune System Diseases (607) · Autoimmune Diseases of the Nervous System (606) · Autoimmune Diseases (601) · Nervous System Diseases (600) · Demyelinating Diseases (596) · Multiple Sclerosis (311) · Pathological Conditions, Signs and Symptoms (132) · Pathologic Processes (97) · Disease Attributes (86) · Chronic Disease (72) · Signs and Symptoms (47) · Behavior (25) · Mental Disorders (18) · Neurocognitive Disorders (11)
Interferon beta-1a (52) · Dimethyl Fumarate (42) · Natalizumab (37) · Glatiramer Acetate (31) · Fingolimod Hydrochloride (30) · ocrelizumab (27) · Interferon beta-1b (26) · Rituximab (14) · Alemtuzumab (13) · Methylprednisolone (10) · ofatumumab (10) · peginterferon beta-1a (10) · teriflunomide (10) · Cladribine (9) · Blood Specimen Collection (6)
Biogen (78) · Novartis Pharmaceuticals (30) · Merck KGaA, Darmstadt, Germany (26) · Bayer (17) · Teva Branded Pharmaceutical Products R&D, Inc. (12) · Hoffmann-La Roche (11) · GlaxoSmithKline (9) · Johns Hopkins University (9) · EMD Serono (8) · Genzyme, a Sanofi Company (8) · Tehran University of Medical Sciences (7) · Charite University, Berlin, Germany (6) · Shirley Ryan AbilityLab (6) · Universitätsklinikum Hamburg-Eppendorf (6) · Amsterdam UMC, location VUmc (5)
United States (228) · Germany (105) · France (82) · Italy (71) · Canada (64) · Poland (63) · Spain (63) · United Kingdom (59) · Czechia (55) · Russia (49) · Belgium (47) · Turkey (Türkiye) (42) · Ukraine (41) · Switzerland (35) · Australia (34)
Dr. Norbert Zessack (3) · Terry L Wahls, MD (3) · Aaron L Boster, MD (2) · Anders Svenningsson, MD, PhD (2)
PMID 34882037, PMID 27411694, PMID 27733070, PMID 31654272, PMID 31762387, PMID 32710396, PMID 37745914, PMID 39935588, PMID 26932146, PMID 30144037, PMID 30918100, PMID 31675266, PMID 32426039, PMID 32539719, PMID 33414927, PMID 34035833, PMID 34378446, PMID 36619856, PMID 37272540, PMID 42328798, PMID 12542793, PMID 15864738, PMID 18272891, PMID 23982748, PMID 24131282, PMID 24759263, PMID 25245812, PMID 25442786, PMID 25546364, PMID 26049148, PMID 26121423, PMID 26526385, PMID 27423899, PMID 27590291, PMID 28751099, PMID 28770420, PMID 28835401, PMID 29866196, PMID 31144568, PMID 32447743, PMID 33023488, PMID 33476880, PMID 33969750, PMID 34240656, PMID 34370275, PMID 35003076, PMID 36017780, PMID 36017797, PMID 37061656, PMID 37173129
2015 (10), 2018 (8), 2009 (7), 2014 (7), 2023 (5), 2008 (4), 2016 (4), 2005 (3), 2017 (2), 2004 (1), 2025 (1), R01NS051591 (1), R21HD108587 (1), U01NS045719 (1), UM1AI109565 (1)